Affiliation:
1. Centre for Mechanical Technology and Automation (TEMA) Mechanical Engineering Department University of Aveiro Aveiro 3810‐193 Portugal
2. Intelligent Systems Associate Laboratory (LASI) Guimarães 4800‐058 Portugal
3. Department of Pharmacy and Pharmaceutical Technology and Parasitology University of Valencia Ave. Vicent Andrés Estellés s/n Burjassot Valencia 46100 Spain
4. Department of Biomaterials and Biomedical Technology University Medical Center Groningen (UMCG) University of Groningen Groningen 9713 AV The Netherlands
5. CICECO—Aveiro Institute of Materials Chemistry Department University of Aveiro Aveiro 3810‐193 Portugal
6. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki Helsinki 00014 Finland
Abstract
AbstractCurrent research in cancer therapy focuses on personalized therapies, through nanotechnology‐based targeted drug delivery systems. Particularly, controlled drug release with nanoparticles (NPs) can be designed to safely transport various active agents, optimizing delivery to specific organs and tumors, minimizing side effects. The use of microfluidics (MFs) in this field has stood out against conventional methods by allowing precise control over parameters like size, structure, composition, and mechanical/biological properties of nanoscale carriers. This review compiles applications of microfluidics in the production of core‐shell NPs (CSNPs) for cancer therapy, discussing the versatility inherent in various microchannel and/or micromixer setups and showcasing how these setups can be utilized individually or in combination, as well as how this technology allows the development of new advances in more efficient and controlled fabrication of core‐shell nanoformulations. Recent biological studies have achieved an effective, safe, and controlled delivery of otherwise unreliable encapsulants such as small interfering RNA (siRNA), plasmid DNA (pDNA), and cisplatin as a result of precisely tuned fabrication of nanocarriers, showing that this technology is paving the way for innovative strategies in cancer therapy nanofabrication, characterized by continuous production and high reproducibility. Finally, this review analyzes the technical, biological, and technological limitations that currently prevent this technology from becoming the standard.
Funder
Fundação para a Ciência e a Tecnologia
Reference184 articles.
1. Global Cancer Observatory “Cancer Today ”2023. (accessed: July 2023).
2. American Cancer Society2007. (accessed: July 2023).
3. Remotely Activated Nanoparticles for Anticancer Therapy
4. A Recent Review on Cancer Nanomedicine
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献